Halberd Corporation (OTCMKTS:HALB) has been one of the healthcare companies which has been publishing its research work related to its patented extracorporeal treatment methodology in recent times and has made considerable progress.
The company has demonstrated that the process could be deployed to combat a wide range of medical conditions and this morning Halberd made another significant announcement that investors could take a look into. The company announced this morning that following the fruitful research that has been conducted thus far, it has decided to create a team of researchers who are going to apply the methodology to cancer treatment.
Halberd announced that since it had been already established that the extracorporeal treatment method had shown such widespread effectiveness the management decided that it was the decision to look into cancer treatments that could no longer be delayed.
The subgroup of researchers that the company has established is going to be made up of personnel who are already members of the technical team. It is a significant development for the company and considering the sheer size of the cancer treatment market, if the extracorporeal treatment method proves to be effective then it could open up a massive new opportunity for Halberd. That is one of the major reasons why investors may get excited about the stock following the announcement.
In addition to that, there was other important news that was shared by the company with regards to this cancer treatment research subgroup. If the efforts of the subgroup proved to be successful, then it might be spun off into a new company altogether and then Halberd shareholders could be provided dividends in the form of shares in the new entity.
This is a strategy that the company hopes will help the two entities in sharing technological expertise but also help Halberd in earning royalties from the spun off firm.
